Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from GT Biopharma ( (GTBP) ) is now available.
GT Biopharma held its annual meeting of stockholders on July 24, 2025, where several key proposals were voted upon. The election of four board members, ratification of the appointment of independent accountants, approval of executive compensation, issuance of additional shares, and an amendment to the incentive plan were all approved, indicating strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
Average Trading Volume: 85,367
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.67M
See more data about GTBP stock on TipRanks’ Stock Analysis page.